124I-F8IL10

124I-F8IL10 is an investigational radiolabeled immunocytokine and biologic fusion protein developed for positron emission tomography (PET) imaging. It consists of the fully human fusion protein F8-IL10 (also known as Dekavil or PF-06687234) labeled with the positron-emitting radioisotope iodine-124 (124I). The F8 antibody fragment of the fusion protein selectively targets the extra-domain A (EDA) of fibronectin, a marker of tissue remodeling and angiogenesis that is highly expressed at sites of active inflammation. The interleukin-10 (IL-10) cytokine component acts as an anti-inflammatory mediator. Originally developed by Philogen and licensed to Pfizer, 124I-F8IL10 has been evaluated in Phase 0/1 clinical trials (conducted at VU University Medical Center and other sites) as a diagnostic imaging tracer to assess pharmacokinetics, biodistribution, and inflammatory-site targeting in patients with active rheumatoid arthritis and inflammatory bowel disease (including Crohn's disease and ulcerative colitis).

Brand names

124I-Dekavil

Other names

iodine-124 labeled F8-IL10iodine124 labeled F8-IL10iodine 124 labeled F8-IL10124I-labeled F8-IL10[124I]I-F8-IL10[124I]I-F8-IL10 fusion protein[124I]-iodobenzoyl-PF-06687234